Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
This study has been completed.
Study NCT00052377 Information provided by National Cancer Institute (NCI)
First Received: January 24, 2003 Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Additional conditions recognized in this trial
Mycoses
Mycosis Fungoides
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
aldesleukin
recombinant interleukin-12
Additional drug interventions recognized in this trial
Interleukin-12
Interleukin-2
More general drug interventions related to this trial
Adjuvants, Immunologic
Analgesics
Analgesics, Non-Narcotic
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antineoplastic Agents
Antiviral Agents
Central Nervous System Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
University of Pennsylvania
National Cancer Institute (NCI)
Back to top of Main Content
